Breast cancer intratumor genetic heterogeneity: Causes and implications

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1021-1032

  Ng, Charlotte Ky ^a   Pemberton, Helen N ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

breast cancer; clonal evolution; drug resistance; genomic instability; intratumor heterogeneity

Indexed keywords

BCR ABL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; PROTEIN MSH2; STEM CELL FACTOR RECEPTOR; VON HIPPEL LINDAU PROTEIN;

AHNAK GENE; BCR ABL GENE; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; DRUG MECHANISM; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KDM5C GENE; MSH2 GENE; MUTATIONAL ANALYSIS; ONCOGENE C KIT; PHARMACOGENETICS; PHENOTYPIC VARIATION; REVIEW; SETD2 GENE; TUMOR SUPPRESSOR GENE; VHL GENE;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASTIC STEM CELLS;

EID: 84867082692     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.85     Document Type: Review

References (108)

1. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805(1), 105-117 (2010).
2. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010).
3. Pleasance ED, Stephens PJ, O'Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010).
4. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
5. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196 (2010).
6. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 145(1), 30-38 (2011).
7. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N. Engl. J. Med. 363(16), 1532-1543 (2010).
8. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011).
9. Curtis C, Shah SP, Chin S-F et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
10. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378(9805), 1812-1823 (2011).
11. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat. Rev. Clin. Oncol. 9(1), 58-64 (2012).
12. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat. Rev. Clin. Oncol. 6(12), 718-730 (2009).
13. Shah SP, Köbel M, Senz J et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360(26), 2719-2729 (2009).
14. Persson M, Andrèn Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl Acad. Sci. USA 106(44), 18740-18744 (2009).
15. Wetterskog D, Lopez-Garcia MA, Lambros MB et al. Adenoid cystic carcinomas constitute a genomically distinct subgroupof triple-negative and basal-like breast cancers. J. Pathol. 226(1), 84-96 (2012).
16. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13(4), e178-e185 (2012).
17. Seol H, Lee HJ, Choi Y et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 25(7), 938-948 (2012).
18. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 13(7), 1036-1043 (2002).
19. Simon R, Nocito A, Hübscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93(15), 1141-1146 (2001).
20. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100(26), 15901-15905 (2003).
21. Bonsing BA, Corver WE, Fleuren GJ, Cleton-Jansen AM, Devilee P, Cornelisse CJ. Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases. Genes. Chromosomes Cancer 28(2), 173-183 (2000).
22. Kuukasjärvi T, Karhu R, Tanner M et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57(8), 1597-1604 (1997).
23. Pandis N, Teixeira MR, Adeyinka A et al. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes. Chromosomes Cancer 22(2), 122-129 (1998).
24. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
25. Anderson K, Lutz C, van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469(7330), 356-361 (2011).
26. Campbell PJ, Pleasance ED, Stephens PJ et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc. Natl Acad. Sci. USA. 105(35), 13081-13086 (2008).
27. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8(5), 329-340 (2008).
28. Schmidt-Kittler O, Ragg T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA. 100(13), 7737-7742 (2003).
29. Gangnus R, Langer S, Breit E, Pantel K, Speicher MR. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10(10), 3457-3464 (2004).
30. Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res. 66(18), 8959-8965 (2006).
31. Hüsemann Y, Geigl JB, Schubert F et al. Systemic spread is an early step in breast cancer. Cancer Cell 13(1), 58-68 (2008).
32. Comen E, Norton L, Massaguè J. Clinical implications of cancer self-seeding. Nat. Rev. Clin. Oncol. 8(6), 369-377 (2011).
33. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 139(7), 1315-1326 (2009).
34. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57(2), 171-192 (2010).
35. Hernandez L, Wilkerson PM, Lambros MB et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J. Pathol. 227(1), 42-52 (2012).
36. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 56(7), 1493-1497 (1996).
37. Yao J, Weremowicz S, Feng B et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 66(8), 4065-4078 (2006).
38. Vincent-Salomon A, Lucchesi C, Gruel N et al.; Breast Cancer Study Group of the Institut Curie. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin. Cancer Res. 14(7), 1956-1965 (2008).
39. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009).
40. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395-399 (2012).
41. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
42. Notta F, Mullighan CG, Wang JC et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469(7330), 362-367 (2011).
43. Mullighan CG, Phillips LA, Su X et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906), 1377-1380 (2008).
44. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 472(7341), 90-94 (2011).
45. Hou Y, Song L, Zhu P et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148(5), 873-885 (2012).
46. Xu X, Hou Y, Yin X et al. Single-cell exome sequencing reveals singlenucleotide mutation characteristics of a kidney tumor. Cell 148(5), 886-895 (2012).
47. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010).
48. Nik-Zainal S, Alexandrov LB, Wedge DC et al.; the Breast Cancer Working Groupof the International Cancer Genome Consortium. Mutational processes molding the genomes of 21 breast cancers. Cell 149(5), 979-993 (2012).
49. Nik-Zainal S, Van Loo P, Wedge DC et al.; Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell 149(5), 994-1007 (2012).
50. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012).
51. Geyer FC, Weigelt B, Natrajan R et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J. Pathol. 220(5), 562-573 (2010).
52. Patani N, Barbashina V, Lambros MB et al. Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype. J. Clin. Pathol. 64(9), 822-828 (2011).
53. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 12(5), 323-334 (2012).
54. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
55. Beckman RA. Mutator mutations enhance tumorigenic efficiency across fitness landscapes. PLoS ONE 4(6), e5860 (2009).
56. Jones S, Chen WD, Parmigiani G et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105(11), 4283-4288 (2008).
57. Turajlic S, Furney SJ, Lambros MB et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22(2), 196-207 (2012).
58. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 11(6), 450-457 (2011).
59. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22(37), 5784-5791 (2003).
60. Natrajan R, Mackay A, Lambros MB et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and-positive breast cancers. J. Pathol. 227(1), 29-41 (2012).
61. McBride DJ, Etemadmoghadam D, Cooke SL et al. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J. Pathol. doi:10.1002/path.4042 (2012) (Epub ahead of print).
62. Umar A, Boyer JC, Thomas DC et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem. 269(20), 14367-14370 (1994).
63. Solomon DA, Kim T, Diaz-Martinez LA et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333(6045), 1039-1043 (2011).
64. O'Hagan RC, Chang S, Maser RS et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2(2), 149-155 (2002).
65. Stephens PJ, Greenman CD, Fu B et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1), 27-40 (2011).
66. Laird PW. Cancer epigenetics. Hum. Mol. Genet. 14 Spec No 1, R65-R76 (2005).
67. Holst CR, Nuovo GJ, Esteller M et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63(7), 1596-1601 (2003).
68. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7), 787-793 (2006).
69. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011).
70. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999).
71. Bae YK, Brown A, Garrett E et al. Hypermethylation in histologically distinct classes of breast cancer. Clin. Cancer Res. 10(18 Pt 1), 5998-6005 (2004).
72. Nosho K, Shima K, Irahara N et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin. Cancer Res. 15(11), 3663-3671 (2009).
73. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer 7, 15 (2008).
74. Gayther SA, Batley SJ, Linger L et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24(3), 300-303 (2000).
75. Wong AK, Shanahan F, Chen Y et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60(21), 6171-6177 (2000).
76. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006).
77. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
78. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003).
79. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3), 259-273 (2007).
80. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007).
81. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 456(7222), 593-598 (2008).
82. Chaffer CL, Brueckmann I, Scheel C et al. Normal and neoplastic nonstem cells canspontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA. 108(19), 7950-7955 (2011).
83. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Invest. 120(2), 636-644 (2010).
84. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol. 13(1), e43-e48 (2012).
85. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002).
86. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
87. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77-88 (2010).
88. Cooke SL, Temple J, Macarthur S et al. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br. J. Cancer 104(2), 361-368 (2011).
89. Maley CC, Galipeau PC, Finley JC et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38(4), 468-473 (2006).
90. Druker BJ, Guilhot F, O'Brien SG et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006).
91. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001).
92. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100(3), 1014-1018 (2002).
93. Willis SG, Lange T, Demehri S et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106(6), 2128-2137 (2005).
94. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
95. Liegl B, Kepten I, Le C et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 216(1), 64-74 (2008).
96. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235-244 (2010).
97. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737), 245-251 (2010).
98. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
99. Martin SA, McCarthy A, Barber LJ et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1(6-7), 323-337 (2009).
100. Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. J. Pathol. 220(2), 281-289 (2010).
101. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29(22), 3008-3015 (2011).
102. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182), 1116-1120 (2008).
103. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68(8), 2581-2586 (2008).
104. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111-1115 (2008).
105. Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer-a reappraisal. Nat. Rev. Clin. Oncol. 7(6), 348-353 (2010).
106. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4(127), 127ps10 (2012).
107. Hudson TJ, Anderson W, Artez A et al.; International Cancer Genome Consortium. International network of cancer genome projects. Nature 464(7291), 993-998 (2010).
108. Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012).